People · Operator
Named in public records as an officer, director or promoter · active 2024–2024 · Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Autolus Therapeutics plc | — | Pharma | Series D+ | $200.0M | $2.4B | 2024 |
Christopher Vann at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Christopher Vann on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| John H Johnson | 1 | 4 |
| WILLIAM D. YOUNG | 1 | 4 |
| Martin H. Murphy | 1 | 2 |
| Brent Rice | 1 | 2 |
| Martin Pule | 1 | 1 |
| Cynthia H. Butitta | 1 | 1 |
| Robert H. Azelby | 1 | 1 |
| David Brochu | 1 | 1 |
| Joseph H. Anderson | 1 | 1 |
| Robert H. Iannone | 1 | 1 |
| John H. Berriman | 1 | 1 |
| Elisabeth H. Leiderman | 1 | 1 |
| Robert Dolski | 1 | 1 |
| Christian Itin | 1 | 1 |
| Edgar Braendle | 1 | 1 |
| Linda H. Bain | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.